Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2020-SEP-09 to 2021-NOV-09
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 021
- Report date:
- 2021
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- June 2018
- Deviations:
- yes
- Remarks:
- None of the deviations was considered to have affected the outcome or integrity of the study
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.26 (Sub-Chronic Oral Toxicity Test: Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- May 2008
- Deviations:
- yes
- Remarks:
- None of the deviations was considered to have affected the outcome or integrity of the study
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3100 (90-Day Oral Toxicity in Rodents)
- Version / remarks:
- August 1998
- Deviations:
- yes
- Remarks:
- None of the deviations was considered to have affected the outcome or integrity of the study
- Qualifier:
- according to guideline
- Guideline:
- other: Agricultural Production Bureau, Ministry of Agriculture, Forestry and Fisheries of Japan (JMAFF) Appendix Director General Notification, No. 12-Nousan-8147
- Version / remarks:
- November 2000
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- benzyl butyl cis-cyclohexane-1,2-dicarboxylate
- Cas Number:
- 1931129-39-3
- Molecular formula:
- C19H26O4
- IUPAC Name:
- benzyl butyl cis-cyclohexane-1,2-dicarboxylate
- Test material form:
- liquid
- Details on test material:
- Name of substance: 1,2-Cyclohexanedicarboxylic Acid, 1-butyl 2-(phenylmethyl) ester
Alternative names: benzyl butyl cis-cyclohexane-1,2-dicarboxylate; Santicizer® Platinum P1400
Batch Number: 5840
CAS Numbers: 1931129-39-3 (cis-isomer); 1200806-67-2
Purity: 99.609 % (GC)
Expiration date: 2021-MAR-04
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source (i.e. manufacturer or supplier) and lot/batch number of test material: Valtris Speciality Chemicals (Bridgeport, NJ, USA); Batch Number: 5840
- Purity, including information on contaminants, isomers, etc.: 99.609% (GC)
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Room temperature
- Stability and homogeneity of the test material in the vehicle/solvent under test conditions (e.g. in the exposure medium) and during storage: Homogeneous and stable for 24 hours at room temperature and for seven days when stored refrigerated (2°C to 8°C).
FORM AS APPLIED IN THE TEST (if different from that of starting material) : Clear, oily liquid
OTHER SPECIFICS
- Expiration date: 2021-MAR-04
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:WI(Han)
- Details on species / strain selection:
- The rat is a suitable rodent species for toxicity testing, acceptable to regulatory authorities and for which extensive background data are available.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited (Margate, Kent, CT9 4LT, England)
- Females (if applicable) nulliparous and non-pregnant: Not specified
- Age at study initiation: 5-6 weeks old
- Weight at study initiation: Males: 175 - 223 grams; Females: 118 - 162 grams
- Fasting period before study: Not specified
- Housing: Housed in groups, by sex, in solid-floor cages
- Diet (e.g. ad libitum): Teklad 2014C Rodent Maintenance Diet (Envigo RMS (UK) Limited) ad libitum
- Water (e.g. ad libitum): mains tap water (in bottles) ad libitum
- Acclimation period: 7 days
DETAILS OF FOOD AND WATER QUALITY:
It was considered that none of the contaminants that were monitored was present at a level that might have prevented the study objective from being achieved. Certificates of analysis for diet and water are retained within the CRO Sequani.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20°C to 24°C
- Humidity (%): 40-70%
- Air changes (per hr): Room airconditioned (number of air changes not specified)
- Photoperiod (hrs dark / hrs light): 12 hrs dark / 12 hrs light
IN-LIFE DATES: From: 2020-SEP-03 To: 2020-DEC-22
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The oral route of administration corresponds to a possible route of human exposure during manufacture, use, or handling,
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test material was formulated within the stability period, for each group separately, as a suspension in corn oil by weighing directly into the final preparation container, with the required quantity of vehicle needed to make up to final weight and stirred until homogeneous. Formulations were divided into daily aliquots and stored refrigerated (2°C to 8°C) and stirred from at least 15 minutes before the start of dosing until the completion of their use for dosing, to ensure thorough re-suspension and homogeneity.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Corn oil (justification not specified) - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration Analyses:
Sets of samples (for analysis or for contingency) were taken from each test material formulation prepared for use on the first day of dosing and on one day towards the end of the dosing period. Samples were analysed under Covance Reference Number 8451750 using the method validated in Covance Study Number: LB14VL (2020).
Homogeneity and Stability:
Homogeneity and stability of test material formulations prepared at concentrations of 3.75 and 250 mg/mL, spanning those used in this study (25 to 250 mg/mL), were examined in an earlier formulation validation study (Envigo Study Number: S56026 (2018)). - Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Once daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Group 1 (Control - corn oil)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Remarks:
- Group 2 (Low dose)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Remarks:
- Group 3 (Intermediate dose)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- Group 4 (High dose)
- No. of animals per sex per dose:
- 10/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Dose levels were selected in consultation with the Sponsor after examining existing toxicity data (14-day Repeated Dose Oral (Gavage) Range Finding Toxicity Study in the Rat. Envigo Study Number: S56026 and a 28 Day Oral (Gavage) Toxicity Study in the Rat with a 15 Day Treatment-Free Period. Sequani Study Number: JSK0016). The high dose level of 1000 mg/kg/day selected is the limit dose for this type of study and this dose level was expected to produce some toxicity, such as a reduction in body weight gain or food intake, but not excessive lethality that would prevent meaningful evaluation. The mid-dose level selected was 300 mg/kg/day, which was the approximate geometric mean between the high and low dose, was expected to produce minimal to moderate toxicity. The low dose level of 100 mg/kg/day was selected with the expectation that it would produce no observable indications of toxicity.
- Rationale for animal assignment (if not random):
Allocation to groups was performed using the Provantis stratified randomisation procedure based on individual body weights recorded on arrival. The cages were positioned in the battery using a randomised cage allocation procedure
- Fasting period before blood sampling for clinical biochemistry: No
- Other:
Animals were dosed once daily for at least 90 days (up to 15 weeks), by gavage, using a rubber catheter and disposable syringe at a constant dose volume of 4 mL/kg body weight, until the day before necropsy. Individual doses were adjusted according to the most recent body weight.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: examined twice daily for mortality and morbidity
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: examined daily for clinical signs of toxicity or changes in behaviour and appearance from Day 6 onwards. Each animal was given a detailed clinical examination weekly from the start of treatment. From the start of dosing, animals were observed approximately one to two hours after dosing, based on
completion of dosing for the study.
BODY WEIGHT: Yes
- Time schedule for examinations: All animals were weighed at the start of dosing and then weekly until necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
Amount of food consumed by each cage of animals was recorded at the start of dosing and weekly during the treatment period.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Both eyes of all animals were examined before the start of treatment. All animals from each of the control and high dose groups were also examined in Week 13
- Dose groups that were examined: All dose groups
Examinations were performed using direct and indirect ophthalmoscopy after previous use of a mydriatic agent
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Day of necropsy
- Anaesthetic used for blood collection: Yes (isoflurane anaesthesia)
- Animals fasted: No
- How many animals: all animals
- Parameters checked in table [No.2] were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Day of necropsy
- Animals fasted: No
- How many animals: All animals
- Parameters checked in table [No.3] were examined.
PLASMA/SERUM HORMONES/LIPIDS: Yes
- Time of blood sample collection: Day of necropsy
- Animals fasted: No
- How many animals: all animals
Blood samples (0.2 mL) were taken from the sublingual vein under isoflurane anaesthesia into gel separator tubes and allowed to clot for at least 30 minutes at room temperature. All animals were sampled on the day of necropsy between 09.00 and 11.00; animals of the same sex were bled within one hour during this time period. Animals were not fasted prior to blood sampling and were sampled in a random cage order. All samples were centrifuged (3000 g, 10 minutes, at approximately 4°C) and the resultant serum was aliquoted into two tubes (Aliquot 1 contained 50 μL and Aliquot 2 contained all remaining serum) and stored frozen (< -70°C) until analysis. Samples were analysed for thyroxine (T4), triiodothyronine (T3) and thyroid stimulating hormone (TSH), using validated method BMK062MA (Sequani Study number SEQ0361 (2019)).
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: All animals were observed once weekly, starting pre-dose, for their behaviour both within their cage and then after placement in an open arena .
- Dose groups that were examined: All dose groups
- Battery of functions tested: sensory activity / grip strength / motor activity: During Weeks 13 and 15, sensorimotor responses to visual, acoustic, tactile or proprioceptive stimuli, grip strength and motor activity were recorded for all animals
IMMUNOLOGY: No
OTHER:
VAGINAL SMEARS:
On the day of necropsy, vaginal smears were taken by lavage. The smear was examined under light microscopy and the stage of the oestrous cycle was recorded. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 4)
All animals were killed by exposure to carbon dioxide gas in a rising concentration, weighed and examined externally. The abdominal cavity was opened and the animals were exsanguinated from the caudal vena cava. The cranial and thoracic cavities were opened, a full internal examination was performed and all macroscopic abnormalities were recorded. Organs listed in Table no. 4 were weighed after trimming of fat and other contiguous tissue (contralateral organs were weighed together).
HISTOPATHOLOGY: Yes (see table 5)
For all animals, with the exception of the eyes, brain, adrenals, bone marrow smear, Harderian glands, optic nerves and testes, either whole organs or samples of the tissues listed in Table no. 5 were preserved in 10 % buffered formalin. The eyes, Harderian glands and optic nerves were fixed in Davidson’s solution, the adrenals, brain and the testes were fixed in Modified Davidson’s solution for approximately 24 to 72 hours and then transferred to 10 % buffered formalin. The bone marrow smears were fixed in methanol and stained but, in the absence of any haematological reasons for doing so, they were not examined.
Initially, for all control and high dose animals, the specified tissues were wax embedded, cut at a nominal thickness of 4 μm to 5 μm, stained with haematoxylin and eosin and examined microscopically. Following treatment-related findings seen in high dose animals, examination of the thyroids, liver and urinary bladder was then extended to all toxicity assessment animals. - Statistics:
- Data were processed to give group mean values and standard deviations, where appropriate. Where the data allowed, the following methods were used for statistical analysis, comparing Groups 2, 3 and 4 against Group 1.
Depending on the nature of the data set that was to be analysed, appropriate tests were applied, as indicated in Table 2. Where parametric tests were appropriate they were preceded by a check for homogeneity of variance using the Levene test and, where available, the Shapiro-Wilks test for normality. If either of these two assumptions failed, a log transformation was applied before retesting. If the transformation failed, appropriate non-parametric tests were applied.
Probability values of less than 5% were regarded as providing sufficient evidence to reject the null hypothesis and therefore statistical significance was identified at the p<0.05 level. For illustrative purposes, significance levels of p<0.01 and p<0.001 were also noted. Further details are provided in Table no. 6.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No signs of clinical toxicity were observed through the study period.
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality was observed through the study period.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- There was no effect on body weight or body weight gain in female rats at any dose level or in male rats given 100 mg/kg/day or 300 mg/kg/day. A slight (7%), non-statistically significant lowering of overall body weight gain was observed in males given 1000 mg/kg/day, when compared with the corresponding controls.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption was unaffected by treatment.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related ocular changes or abnormalities were observed after exposure to the test material.
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg/day, mean platelet volume (MPV) was statistically significantly higher than controls in males (p≤0.001) and females (p≤0.05), and platelet distribution width was higher than controls in males (p≤0.05). Mean cell volume (MCV) was statistically significantly lower than controls in male rats (p≤0.01) and female rats (p≤0.05) given 1000 mg/kg/day. Reticulocyte haemoglobin content (CHr) was lower than controls in males at all dose levels (p≤0.05 to p≤0.001) and haemoglobin distribution width (HDW) in female rats was statistically significantly higher than controls at 300 or 1000 mg/kg/day (p≤0.01).These changes were marginal, with most or all individual values within the historical control range, and as they had no effect on the primary red cell parameters, were considered not to be adverse.
Mean reticulocyte corpuscular volume (MCVr) in male rats given 1000 mg/kg/day was statistically significantly lower than the corresponding control mean. However, this was due to three high individual control values (i.e. values above the upper limit of the historical control range) rather than an effect of the test material.
White blood cell count in males given 1000 mg/kg/day was statistically significantly higher than controls (p≤0.05), primarily due to slight increases in absolute lymphocyte and monocyte counts. However, all individual values were within the historical control range and since these changes were minor in nature, considered not to be adverse. - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- White blood cell count in males given 1000 mg/kg/day was statistically significantly higher than controls (p≤0.05), primarily due to slight increases in absolute lymphocyte and monocyte counts. However, all individual values were within the historical control range and since these changes were minor in nature, considered not to be adverse.
Plasma cholesterol in both sexes was higher compared to controls at 300 (p≤0.05 to p≤0.01) and 1000 mg/kg/day (p≤0.01). All individual values, with the exception of one female given 1000 mg/kg/day, and one male given 300 or 1000 mg/kg/day, were within the historical control background ranges.
Triglyceride concentration was statistically significantly higher in males given 300 or 1000 mg/kg/day (p≤0.05 and p≤0.01, respectively) but most individual values for were within the historical control background ranges.
Plasma calcium was statistically significantly higher than controls in males at 1000 mg/kg/day (p≤0.001). However, all individual values were within the historical control background range. Statistically significant (p≤0.05) increases in plasma sodium concentration at 300 and 1000 mg/kg/day, and lowering of plasma chloride concentrations (p≤0.01) at 1000 mg/kg/day were observed in male rats, however most or all individual values were within the historical control
range.
These changes in plasma cholesterol, triglyceride, calcium, sodium, and chloride levels were relatively minor and, in the absence of corroborative pathology changes, were considered not to be adverse. - Endocrine findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In male rats given 1000 mg/kg/day, group mean TSH concentration was 2.6-fold higher than controls (p≤0.01), where 7 out 10 males were above the mean historical control range. In females at this dose level, there was a similar 2.5-fold increase in TSH concentration when compared with corresponding controls where 4 out of 10 females were above the mean historical control range although, this did not achieve statistical significance.
In female rats, there was a marginal, but statistically significant (p≤0.05) increase in group mean T4 concentration at 1000 mg/kg/day where 9 out 10 females were above the mean historical control range. The increase in TSH concentration was considered to be associated with the rodent-specific adaptive epithelial hypertrophy in the thyroid gland and, in the absence of any marked changes in T3 or T4 concentrations, this finding was considered to be non-adverse. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Several instances of hyper- and hypoactivity in the arena were observed in all dose groups during the weekly functional observations throughout the study in both sexes. However, as the incidence was low and the pattern and frequency of these observations not dose-related, this observation was not considered to be treatment-related. At 100 mg/kg/day on Day 77, two males had a straub tail and one female excessively reared in the arena. On Day 91 of the study, at 300 mg/kg/day, one male displayed an excessive response to tail-pinching. These observations were considered not to be treatment-related due to their infrequent and transient nature. At 1000 mg/kg/day, in males and females, there were two and one instances of slight salivation on removal from the home cage, respectively, and one instance of salivation in the arena in males.
Mean movement counts and distance travelled for all groups, including control rats, generally decreased with time in both sexes. In males, there was a statistically significant increase in movement count and distance travelled during Period 1 at 300 and 1000 mg/kg/day (p≤0.05), but these differences were not dose-related. In female rats given 1000 mg/kg/day, during Period 1, there was a statistically significant increase in distance travelled (p≤0.05), and a decrease in time at rest (p≤0.05). Thereafter, there were no statistically significant intergroup differences in movement counts or distance travelled at any dose level, in either sex. As these inter-group differences were observed in Period 1 only and not at any other time point, they were considered unlikely to be treatment-related.
Fore and hindlimb grip strength was statistically significantly increased in females at 1000 mg/kg/day (p≤0.05) compared with controls. However, as this reduction was not consistent between sexes, it was considered likely to be due to chance rather than any effect of the test material. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Liver:
Body weight-related liver weight in female rats given 300 or 1000 mg/kg/day and in male rats at all dose levels were statistically significantly higher than controls (p≤0.05 to p≤0.001). Most individual body weight-related liver weights for male rats given 1000 mg/kg/day were above the upper limit of the historical background range, with group mean relative liver weight being 35% and 17% higher than corresponding controls, for males and females respectively, correlating to the adaptive centrilobular hypertrophy of the liver seen microscopically.
Thyroid:
In male rats, mean absolute and body weight-related thyroid weights were statistically significantly higher (p≤0.05 to p≤0.01) than the control mean across all dose groups in a dose-related manner, by up to 2.3-fold, correlating with the adaptive follicular epithelial hypertrophy seen microscopically in the thyroid. Most individual values were, however, within the historical background range.
Kidney:
Body weight-related kidney weights for males (p≤0.001) and females (p≤0.05) given 1000 mg/kg/day were statistically significantly higher than controls, by 12% and 5%, respectively. All individual values were within the historical background range, and there were no microscopic correlates. Therefore, this change was considered not to be of toxicological significance.
Spleen:
In males, absolute and body weight-related spleen weight was higher than controls by up to 24% at 1000 mg/kg/day (p≤0.001). All individual body weight-related spleen weights were within the historical background range, and there were no microscopic correlates, therefore this change was considered not to be of toxicological significance.
Epididymides:
Absolute epididymis weight at 300 and 1000 mg/kg/day was statistically significantly lower than controls (p≤0.05). However, this was not strictly dose-related, and there were no microscopic correlates, therefore this intergroup difference was considered to be due to chance rather than any effect of the test material. - Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A variety of spontaneous changes were noted in the control and treated animals with no indication of an effect of treatment. The spectrum of these findings was generally consistent with changes encountered in rats of this age kept under laboratory conditions.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Histopathology revealed treatment-related effects in the liver (hypertrophy centrilobular), thyroid glands (hypertrophy of the follicular epithelium and increased basophilia of colloid), and urinary bladder (hyperplasia of the urothelium). These effects in the liver and thyroid were considered to be rodent specific adaptive responses. Hyperplasia of the urothelium of the urinary bladder was considered likely to be a local effect.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- At necropsy, the stage of oestrous was similar across all groups.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Systemic toxicity
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
The mean concentrations of 1,2-Cyclohexanedicarboxylic Acid, 1-butyl 2-(phenylmethyl) ester in test formulations analysed for the study were within 6 % of nominal concentrations which was within applied limits of +10/-15% from nominal, confirming accurate formulation. The coefficient of variation values were less than 4%, which is within applied limits of ≤5 %, confirming the precision of analysis.
Table 7. Results of Formulation analysis |
|||||||||
Occasion |
Group |
Nominal concentration (mg/mL) |
Analyzed concentration (mg/mL) |
RME (%) |
CV (%) |
Procedural Recoveries (%) |
|||
Top |
Middle |
Bottom |
Mean |
||||||
First occasion |
1 |
0 |
- |
ND, ND |
- |
- |
- |
- |
- |
2 |
25 |
25.5 |
25.4 |
25.6 |
25.5 |
+2.0 |
0.33 |
101.5 |
|
3 |
75 |
74.7 |
76.1 |
76.3 |
75.7 |
+0.9 |
1.14 |
102.9 |
|
4 |
250 |
255 |
251 |
260 |
255 |
+2.0 |
1.79 |
10.24 |
|
|
|||||||||
One occasion towards end of the study |
1 |
0 |
- |
ND, ND |
- |
- |
- |
- |
- |
2 |
25 |
25.3 |
26.9 |
26.8 |
26.4 |
+5.6 |
3.51 |
110.0 |
|
3 |
75 |
78.9 |
79.0 |
78.3 |
78.8 |
+5.1 |
0.47 |
104.5 |
|
4 |
250 |
232, 2311 |
244, 2401 |
242, 2541 |
241 |
-3.6 |
3.61 |
94.12, 95.52, 94.82 |
RME Relative mean error, representing the deviation from nominal
ND Not detected
CV Coefficient of variation
1 Contingency samples
2 Recovery samples are outside of validation limits (96.1 – 111.1 %), however recovery results were at roughly 95%, which was within 10% of nominal and as samples were not corrected for recovery values, this was considered to have no impact on the integrity of the study, therefore these results were reported.
Table 8. Functional Observations: Motor activity (Group mean values) |
|||||||
Group |
|
Movements Counts Period 1 (Day Number) |
Movements Counts Period 2 (Day Number) |
Movements Counts Period 3 (Day Number) |
Movements Counts Period 4 (Day Number) |
Movements Counts Period 5 (Day Number) |
Movements Counts Period 6 (Day Number) |
90 (#) |
90 (#) |
90 (#) |
90 (#) |
90 (#) |
90 (#) |
||
Males |
|||||||
Group 1 (Control – 0 mg/kg/day) |
Mean |
1251.3 |
761.7 |
663.6 |
749.1 |
584.6 |
477.0 |
SD |
362.0 |
212.7 |
225.5 |
275.0 |
139.7 |
350.3 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
↑ |
↑ |
↑ |
↓ |
↓ |
↓ |
|
|
|||||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
1466.0 |
708.1 |
602.2 |
571.1 |
550.4 |
391.5 |
SD |
307.5 |
196.3 |
168.3 |
255.0 |
240.5 |
301.4 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
- |
- |
- |
- |
- |
|
|
|||||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
1717.3 |
901.4 |
650.4 |
781.9 |
595.4 |
323.3 |
SD |
222.6 |
182.3 |
313.2 |
545.5 |
281.1 |
263.5 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.05* |
- |
- |
- |
- |
- |
|
|
|||||||
Group 4 (P1400 1000 mg/kg/day) |
Mean |
1545.2 |
925.6 |
703.8 |
739.0 |
557.6 |
343.5 |
SD |
428.8 |
323.9 |
367.5 |
447.3 |
323.7 |
185.9 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.05* |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
(#) - Williams, Anova & Dunnett: * = p ≤ 0.05
Note: a period equates to an interval of 10 minutes
Table 9. Functional Observations: Motor activity (Group mean values) |
|||||||
Group |
|
Distance Travelled Period 1 (cm) (Day Number) |
Distance Travelled Period 2 (cm) (Day Number) |
Distance Travelled Period 3 (cm) (Day Number) |
Distance Travelled Period 4 (cm) (Day Number) |
Distance Travelled Period 5 (cm) (Day Number) |
Distance Travelled Period 6 (cm) (Day Number) |
90 (#) |
90 (# 1) |
90 (#) |
90 (#) |
90 (#) |
90 (#; # 2) |
||
Males |
|||||||
Group 1 (Control – 0 mg/kg/day) |
Mean |
4506.5 |
2760.3 |
2418.9 |
2731.4 |
2136.3 |
1685.3 |
SD |
1254.0 |
748.8 |
825.2 |
998.5 |
473.4 |
1249.4 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
↑ |
↑ |
↑ |
↓ |
↓ |
↓ |
|
|
|||||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
5207.7 |
2516.7 |
2184.6 |
2052.4 |
1987.5 |
1422.4 |
SD |
941.6 |
588.2 |
611.4 |
876.1 |
772.9 |
1095.2 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
- |
- |
- |
- |
- |
|
|
|||||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
5926.4 |
3125.7 |
2257.4 |
2698.0 |
2120.9 |
1135.6 |
SD |
761.5 |
540.5 |
1114.2 |
1713.8 |
1010.0 |
956.9 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.05* |
- |
- |
- |
- |
- |
|
|
|||||||
Group 4 (P1400 1000 mg/kg/day) |
Mean |
5636.9 |
3343.1 |
2528.5 |
2646.9 |
2088.0 |
1262.3 |
SD |
1409.3 |
1122.1 |
1196.0 |
1567.0 |
1199.7 |
675.0 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.05* |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
|
Females |
|||||||
Group 1 (Control – 0 mg/kg/day) |
Mean |
4932.7 |
3201.8 |
2818.6 |
2532.5 |
1842.3 |
1998.9 |
SD |
1503.5 |
798.9 |
1168.3 |
1136.5 |
983.4 |
1399.8 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
↑ |
↑ |
↓ |
↓ |
↑ |
↓ |
|
|
|||||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
5472.0 |
3538.5 |
2780.7 |
2462.0 |
2724.9 |
2069.3 |
SD |
1119.9 |
1061.8 |
982.4 |
716.1 |
956.0 |
396.2 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
5747.9 |
3794.3 |
3240.2 |
2528.6 |
2378.4 |
1605.9 |
SD |
1415.3 |
1259.4 |
1264.7 |
1105.4 |
1278.6 |
1319.3 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
- |
- |
- |
- |
- |
|
|
|||||||
Group 4 (P1400 1000 mg/kg/day) |
Mean |
6361.8 |
3465.2 |
2051.8 |
1948.4 |
2024.7 |
1558.5 |
SD |
1521.9 |
1264.1 |
1256.8 |
1308.0 |
1392.2 |
1557.4 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.05* |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
(#) - Williams, Anova & Dunnett: * = p ≤ 0.05
(#1) - Williams, Anova & Dunnett(Log)
(#2) - Shirley, Kruskal-Wallis & Steel (Females)
Note: a period equates to an interval of 10 minutes
Table 10. Functional Observations: Motor activity (Group mean values) |
|||||||
Group |
|
Time at Rest Period 1 (sec) (Day Number) |
Time at Rest Period 2 (sec) (Day Number) |
Time at Rest Period 3 (sec) (Day Number) |
Time at Rest Period 4 (sec) (Day Number) |
Time at Rest Period 5 (sec) (Day Number) |
Time at Rest Period 6 (sec) (Day Number) |
90 (#) |
90 (#) |
90 (#) |
90 (#) |
90 (# 1) |
90 (# 1) |
||
Females |
|||||||
Group 1 (Control – 0 mg/kg/day) |
Mean |
244.58 |
334.84 |
360.27 |
390.63 |
438.42 |
434.04 |
SD |
52.59 |
52.59 |
83.26 |
78.05 |
88.59 |
114.73 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
↓ |
↓ |
↑ |
↑ |
↓ |
↑ |
|
|
|||||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
208.73 |
312.08 |
368.36 |
398.39 |
382.79 |
423.86 |
SD |
36.40 |
57.02 |
49.43 |
55.08 |
60.41 |
38.78 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
213.12 |
311.86 |
365.61 |
399.92 |
400.14 |
453.98 |
SD |
41.35 |
50.96 |
68.77 |
70.04 |
95.92 |
114.93 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
- |
- |
- |
- |
- |
|
|
|||||||
Group 4 (P1400 1000 mg/kg/day) |
Mean |
197.05 |
339.0 |
430.51 |
450.14 |
443.46 |
468.96 |
SD |
52.82 |
53.95 |
90.29 |
100.15 |
99.29 |
106.08 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.05* |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
(#) - Williams, Anova & Dunnett: * = p ≤ 0.05
(#1) - Williams, Anova & Dunnett (Log)
Note: a period equates to an interval of 10 minutes
Table 11. Functional observations: Grip strength (Group mean values – Females) |
|||
Group |
|
Forelimb Mean (g) (Day Number) |
Hindlimb Mean (g) (Day Number) |
|
|
103 (#) |
103 (#) |
Group 1 (Control – 0 mg/kg/day) |
Mean |
450.07 |
317.63 |
SD |
121.18 |
46.52 |
|
N |
10 |
10 |
|
Trend |
↑ |
↑ |
|
|
|||
Group 2 (P1400 100 mg/kg/day) |
Mean |
509.00 |
337.90 |
SD |
104.04 |
55.27 |
|
N |
10 |
10 |
|
|
|||
Group 3 (P1400 300 mg/kg/day) |
Mean |
469.70 |
287.23 |
SD |
114.26 |
61.65 |
|
N |
10 |
10 |
|
Trend |
>0.05 |
>0.05 |
|
|
|||
Group 4 (P1400 1000 mg/kg/day) |
Mean |
580.07 |
379.90 |
SD |
147.38 |
73.43 |
|
N |
10 |
10 |
|
Trend |
≤0.05* |
≤0.05 |
(#) - Williams, Anova & Dunnett: * = p ≤ 0.05
Table 12. Select Haematology Parameters (Group mean values) |
|||||||||||
Group |
|
Males |
|||||||||
MCV fl (Week Number) |
MPV fl (Week Number) |
PDW % (Week Number) |
MCVr fl (Week Number) |
CHr pg (Week Number) |
WBC 10^3/uL (Week Number) |
Lymph 10^3/uL (Week Number) |
Mono 10^3/uL (Week Number) |
LUC 10^3/uL (Week Number) |
Eosin % (Week Number) |
||
15 (#) |
15 (# 1) |
15 (#) |
15 (#) |
15 (#) |
15 (#) |
15 (#) |
15 (#) |
15 (# 2) |
15 (# 1) |
||
Group 1 (Control – 0 mg/kg/day) |
Mean |
52.96 |
7.99** |
48.78 |
66.28 |
19.15 |
5.358 |
4.466 |
0.076 |
0.019 |
1.26 |
SD |
1.11 |
0.20 |
5.61 |
0.78 |
0.37 |
0.963 |
0.966 |
0.025 |
0.010 |
0.51 |
|
N |
10 |
9 |
9 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
↓ |
↑ |
↑ |
↓ |
↓ |
↑ |
↑ |
↑ |
↑ |
↓ |
|
|
|||||||||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
52.09 |
8.31* |
49.84 |
65.39 |
18.75 |
4.978 |
4.079 |
0.084 |
0.019 |
1.30 |
SD |
1.08 |
0.27 |
1.87 |
1.11 |
0.42 |
0.531 |
0.449 |
0.020 |
0.007 |
0.26 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
- |
- |
- |
- |
≤0.05* |
- |
- |
- |
- |
- |
|
|
|||||||||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
51.99 |
7.93 |
49.14 |
65.24 |
18.76 |
5.401 |
4.529 |
0.089 |
0.020 |
1.26 |
SD |
1.07 |
0.29 |
2.90 |
1.23 |
0.50 |
1.241 |
1.035 |
0.038 |
0.011 |
0.55 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
≤0.05* |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
|
|
|||||||||||
Group 4 (P1400 1000 mg/kg/day) |
Mean |
50.72 |
8.39 |
53.11 |
63.55 |
18.15 |
6.450 |
5.440 |
0.113 |
0.032 |
0.77 |
SD |
2.11 |
0.17 |
4.60 |
1.98 |
0.62 |
0.953 |
0.977 |
0.038 |
0.018 |
0.22 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.01** |
≤0.001*** |
≤0.05* |
≤0.001*** |
≤0.001*** |
≤0.05* |
≤0.05* |
≤0.05* |
≤0.05* |
≤0.05* |
(#) & (# 1) - Williams, Anova & Dunnett: * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001
(#2) - Williams, Anova & Dunnett(Log): * = p ≤ 0.05
Table 13. Select Haematology Parameters (Group mean values) |
|||||||
Group |
|
Females |
|||||
MCV fl (Week Number) |
MCH pg (Week Number) |
MCHC g/dl (Week Number) |
RDW % (Week Number) |
HDW g/dl (Week Number) |
MPV fl (Week Number) |
||
15 (#) |
15 (# 1) |
15 (# 1) |
15 (#) |
15 (#) |
15 (# 1) |
||
Group 1 (Control – 0 mg/kg/day) |
Mean |
55.40 |
18.93* |
34.16** |
10.95* |
1.958 |
8.00 |
SD |
1.27 |
0.46 |
0.46 |
0.37 |
0.066 |
0.19 |
|
N |
10 |
10 |
10 |
10 |
10 |
9 |
|
Trend |
↓ |
↓ |
↑ |
↑ |
↑ |
↑ |
|
|
|||||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
55.39 |
18.73 |
33.87 |
11.16 |
1.979 |
8.08 |
SD |
2.01 |
0.37 |
0.83 |
1.64 |
0.155 |
0.18 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
- |
- |
- |
- |
>0.05 |
- |
|
|
|||||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
55.01 |
19.19 |
34.89* |
11.66 |
2.103 |
7.97 |
SD |
1.19 |
0.43 |
0.55 |
2.08 |
0.149 |
0.18 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
- |
- |
- |
≤0.01** |
>0.05 |
|
|
|||||||
Group 4 (P1400 1000 mg/kg/day) |
Mean |
53.98 |
18.64 |
34.54 |
11.29 |
2.050 |
8.28 |
SD |
0.97 |
0.47 |
0.50 |
0.37 |
0.067 |
0.36 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.05* |
>0.05 |
>0.05 |
>0.05 |
≤0.01** |
≤0.05* |
(#) - Shirley, Kruskal-Wallis & Steel: * = p ≤ 0.05
Table 14. Select Clinical Chemistry Parameters (Group mean values) |
|||||||||
Group |
|
Males |
Females |
||||||
Na mmol/l (Week Number) |
Cl mmol/l (Week Number) |
Ca mg/dl (Week Number) |
Chol mg/dl (Week Number) |
Trigs mg/dl (Week Number) |
Glob g/dl (Week Number) |
A/G ratio (Week Number) |
Chol mg/dl (Week Number) |
||
15 (#) |
15 (#) |
15 (#) |
15 (#) |
15 (#) |
15 (# 1) |
15 (#) |
15 (#) |
||
Group 1 (Control – 0 mg/kg/day) |
Mean |
141.6 |
102.6 |
10.42 |
65.3 |
146.6 |
2.22*** |
2.21*** |
56.1 |
SD |
1.3 |
1.2 |
0.15 |
10.5 |
38.9 |
0.20 |
0.24 |
12.4 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
↑ |
↓ |
↑ |
↑ |
↑ |
↓ |
↑ |
↑ |
|
|
|||||||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
141.5 |
102.5 |
10.34 |
67.9 |
137.5 |
1.91*** |
2.59*** |
55.8 |
SD |
1.4 |
0.7 |
0.15 |
8.9 |
2.9 |
0.13 |
0.18 |
11.5 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
- |
- |
>0.05 |
>0.05 |
- |
- |
>0.05 |
|
|
|||||||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
142.5 |
102.5 |
10.48 |
80.6 |
195.9 |
2.03* |
2.35 |
67.0 |
SD |
0.8 |
1.3 |
0.19 |
13.0 |
72.3 |
0.16 |
0.21 |
9.1 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.05* |
>0.05 |
>0.05 |
≤0.01** |
≤0.05* |
- |
- |
≤0.05* |
|
|
|||||||||
Group 4 P1400 1000 mg/kg/day |
Mean |
142.9 |
101.0 |
10.79 |
78.9 |
226.7 |
2.28 |
2.12 |
72.0 |
SD |
0.9 |
1.0 |
0.20 |
9.8 |
68.9 |
0.12 |
0.17 |
13.4 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.05* |
≤0.01** |
≤0.001*** |
≤0.01** |
≤0.01** |
>0.05 |
>0.05 |
≤0.01** |
(#) and (# 1) - Williams, Anova & Dunnett: * = p ≤ 0.05; ** = p ≤ 0.01;*** = p ≤ 0.001
Values above or below the limit of quantification have been excluded from the group means
Na: sodium
Ca: calcium
Cl: chlorine
Chol: cholesterol
Trigs: triglyceride
Glob: globulin
A/G: albumin/globulin ratio
Table 15. Thyroid hormone assessment (Group mean values) |
|||||||
Group |
|
Males |
Females |
||||
Mean Total T3 (ng/mL) |
Mean Total T4 (ng/mL) |
Mean Total TSH (ng/mL) |
Mean Total T3 (ng/mL) |
Mean Total T4 (ng/mL) |
Mean Total TSH (ng/mL) |
||
(#) |
(# 1) |
(# 2) |
(#)† |
(# 1)† |
(# 2)† |
||
Group 1 (Control – 0 mg/kg/day) |
Mean |
13.471 |
475.959 |
0.797 |
12.763 |
343.996 |
0.621 |
SD |
4.387 |
37.643 |
0.479 |
9.613 |
58.436 |
0.243 |
|
N |
10 |
10 |
9 |
9 |
10 |
10 |
|
Trend |
↓ |
↓ |
↑ |
↑ |
↑ |
↑ |
|
|
|||||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
13.875 |
478.603 |
0.701 |
10.889 |
331.376 |
1.134 |
SD |
2.430 |
27.709 |
0.435 |
4.327 |
46.663 |
1.639 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
16.150 |
468.248 |
1.455 |
12.173 |
373.460 |
0.958 |
SD |
4.522 |
28.543 |
1.681 |
4.785 |
45.217 |
0.962 |
|
N |
10 |
10 |
10 |
9 |
10 |
9 |
|
Trend |
- |
- |
>0.05 |
- |
>0.05 |
- |
|
|
|||||||
Group 4 (P1400 1000 mg/kg/day) |
Mean |
12.321 |
462.386 |
2.057 |
13.993 |
396.665 |
1.542 |
SD |
2.358 |
20.047 |
1.030 |
3.594 |
43.594 |
1.719 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
>0.05 |
≤0.01** |
>0.05 |
≤0.05* |
>0.05 |
(#) - Williams, Anova & Dunnett
(#1) - Shirley, Kruskal-Wallis & Steel
(#2) - Williams, Anova & Dunnett(Log): ** = p ≤ 0.01
(#)†- Williams, Anova & Dunnett(Log)
(#1)†- Williams, Anova & Dunnett: * = p ≤ 0.05
(#2)†- Shirley, Kruskal-Wallis & Steel
Table 16. Select Organ weights (Group mean values) - Males |
||||||||||||||
Group |
|
Spleen (g) |
Adjusted Spleen Wt |
Spleen % Body Weight |
Liver (g) |
Adjusted Liver Wt |
Liver % Body Weight |
Adjusted Kidneys Wt |
Kidneys % Body Weight |
Epididymides (g) |
Adjusted Epididymides Wt |
Thyroids (g) |
Adjusted Thyroids Wt |
Thyroids % Body Weight |
(#) |
(# 1) |
(#) |
(#) |
(# 1) |
(#) |
(# 1) |
(#) |
(#) |
(# 1) |
(#) |
(# 1) |
(#) |
||
Group 1 (Control – 0 mg/kg/day) |
Mean |
0.573 |
0.570 |
0.131 |
13.921 |
13.766 |
3.162 |
2.461 |
0.565 |
1.596 |
1.586 |
0.0140 |
0.0140 |
0.0032 |
SD |
0.049 |
- |
0.013 |
1.209 |
- |
0.071 |
- |
0.045 |
0.238 |
- |
0.0040 |
- |
0.0010 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
↑ |
↑ |
↑ |
↑ |
↑ |
↑ |
↑ |
↑ |
↓ |
↓ |
↑ |
↑ |
↑ |
|
|
||||||||||||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
0.621 |
0.612 |
0.140 |
14.848 |
14.429 |
3.313 |
2.424 |
0.553 |
1.521 |
1.495 |
0.0182 |
0.0182 |
0.0041 |
SD |
0.068 |
- |
0.016 |
1.930 |
- |
0.180 |
- |
0.022 |
0.196 |
- |
0.0045 |
- |
0.0012 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
- |
- |
- |
- |
≤0.05* |
≤0.05* |
- |
- |
>0.05 |
>0.05 |
≤0.05* |
≤0.05* |
>0.05 |
|
|
||||||||||||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
0.598 |
0.600 |
0.138 |
15.320 |
15.410 |
3.538 |
2.450 |
0.564 |
1.379 |
1.385 |
0.0259 |
0.0259 |
0.0060 |
SD |
0.078 |
- |
0.015 |
1.862 |
- |
0.256 |
- |
0.046 |
0.147 |
- |
0.0056 |
- |
0.0013 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
>0.05 |
>0.05 |
>0.05 |
≤0.001*** |
≤0.001*** |
>0.05 |
>0.05 |
≤0.05* |
≤0.05* |
≤0.001*** |
≤0.001*** |
≤0.001*** |
|
|
||||||||||||||
Group 4 P1400 1000 mg/kg/day |
Mean |
0.684 |
0.695 |
0.162 |
18.031 |
18.514 |
4.270 |
2.723 |
0.631 |
1.423 |
1.453 |
0.0308 |
0.0308 |
0.0074 |
SD |
0.064 |
- |
0.012 |
2.021 |
- |
0.167 |
- |
0.040 |
0.125 |
- |
0.0045 |
- |
0.0015 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Trend |
≤0.001*** |
≤0.001*** |
≤0.001*** |
≤0.001*** |
≤0.001*** |
≤0.001*** |
≤0.001*** |
≤0.001*** |
≤0.05* |
≤0.05* |
≤0.001*** |
≤0.001*** |
≤0.001*** |
(#) - Williams, Anova & Dunnett: * = p ≤ 0.05; *** = p ≤ 0.001
(#1) - Williams, Ancova/Anova & Dunnett: * = p ≤ 0.05; *** = p ≤ 0.001
{Covariate(s): Dead body weight}
Table 17. Select Organ weights (Group mean values) - Females |
|||||
Group |
|
Liver (g) |
Adjusted Liver Wt |
Liver % Body Weight |
Kidneys % Body Weight |
(#) |
(# 1) |
(#) |
(#) |
||
Group 1 (Control – 0 mg/kg/day) |
Mean |
8.567 |
8.446 |
3.494 |
0.651 |
SD |
0.819 |
- |
0.157 |
0.018 |
|
N |
10 |
10 |
10 |
10 |
|
Trend |
↓ |
↓ |
↓ |
↑ |
|
|
|||||
Group 2 (P1400 100 mg/kg/day) |
Mean |
8.506 |
8.522 |
3.515 |
0.637 |
SD |
0.994 |
- |
0.280 |
0.045 |
|
N |
9 |
9 |
9 |
9 |
|
Trend |
- |
>0.05 |
>0.05 |
- |
|
|
|||||
Group 3 (P1400 300 mg/kg/day) |
Mean |
8.925 |
9.007 |
3.722 |
0.668 |
SD |
0.719 |
- |
0.231 |
0.045 |
|
N |
10 |
10 |
10 |
10 |
|
Trend |
>0.05 |
≤0.05* |
≤0.05* |
>0.05 |
|
|
|||||
Group 4 P1400 1000 mg/kg/day |
Mean |
9.901 |
9.926 |
4.104 |
0.686 |
SD |
0.820 |
- |
0.178 |
0.032 |
|
N |
10 |
10 |
10 |
10 |
|
Trend |
≤0.01** |
≤0.001*** |
≤0.001*** |
≤0.05* |
(#) - Williams, Anova & Dunnett: * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001 (#1) - Williams, Ancova/Anova & Dunnett: * = p ≤ 0.05; *** = p ≤ 0.001
{Covariate(s): Dead body weight}
Table 18. Select Histopathology Findings |
||||||||||
|
Males |
Females |
||||||||
Group |
1 |
2 |
3 |
4 |
1 |
2 |
3 |
4 |
||
Dose Level (mg/kg/day) |
0 |
100 |
300 |
1000 |
0 |
100 |
300 |
1000 |
||
Number of rats examined |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||
Liver |
|
|||||||||
Hypertrophy, centrilobular |
Minimal |
0 |
0 |
4 |
8 |
0 |
0 |
2 |
0 |
|
Slight |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Total |
0 |
0 |
4 |
8 |
0 |
0 |
2 |
0 |
||
Thyroid Glands |
|
|||||||||
Hypertrophy, follicular epithelium |
Minimal |
0 |
1 |
2 |
5 |
0 |
0 |
0 |
0 |
|
Slight |
0 |
3 |
5 |
3 |
0 |
0 |
1 |
0 |
||
Total |
0 |
4 |
7 |
8 |
0 |
0 |
1 |
0 |
||
Colloid, increased basophilic concretions |
Slight |
4 |
4 |
6 |
3 |
0 |
0 |
1 |
3 |
|
Moderate |
0 |
0 |
1 |
7 |
0 |
0 |
0 |
0 |
||
Total |
4 |
4 |
7 |
10 |
0 |
0 |
1 |
3 |
||
Urinary Bladder |
|
|||||||||
Hyperplasia, urothelium |
Slight |
0 |
0 |
0 |
5 |
1 |
0 |
0 |
2 |
|
Total |
0 |
0 |
0 |
5 |
1 |
0 |
0 |
2 |
Applicant's summary and conclusion
- Conclusions:
- Based on the lack of adverse treatment-related effects observed through the study period, the No Observed Adverse Effect Level (NOAEL) for 1,2-Cyclohexanedicarboxylic Acid, 1-butyl 2-(phenylmethyl) ester was determined to be 1000 mg/kg/day.
- Executive summary:
A key OECD Guideline 408 sub-chronic toxicity study was conducted to assess the toxicity of the test material (1, 2-Cyclohexanedicarboxylic Acid, 1-butyl 2-(phenylmethyl) ester), when administered by gavage to the rat once daily for at least 90 days.
The test material was administered to Crl:WI(Han) Wistar rats (5/sex/dose) once daily via oral gavage for a period of 90 days at dose levels of 0, 100, 300, or 1000 mg/kg/day in a corn oil vehicle. Animals were subsequently observed for the following parameters: clinical observations, ophthalmoscopy, body weight, food intake, behavioural observations and functional observation battery, vaginal smear on the day of necropsy, haematology, blood chemistry, thyroid hormone assessment, organ weights, macroscopic and microscopic pathology.
No mortality or signs of clinical toxicity were observed through the study period. There was no effect on body weight or body weight gain in female rats at any dose level or in male rats given 100 mg/kg/day or 300 mg/kg/day. A slight (7%), non-statistically significant lowering of overall body weight gain was observed in males given 1000 mg/kg/day, when compared with the corresponding controls. Food consumption was unaffected by treatment. No treatment-related ocular changes or abnormalities were observed after exposure to the test material.
At 1000 mg/kg/day, mean platelet volume (MPV) was statistically significantly higher than controls in males (p≤0.001) and females (p≤0.05), and platelet distribution width was higher than controls in males (p≤0.05). Mean cell volume (MCV) was statistically significantly lower than controls in male rats (p≤0.01) and female rats (p≤0.05) given 1000 mg/kg/day. Reticulocyte haemoglobin content (CHr) was lower than controls in males at all dose levels (p≤0.05 top≤0.001) and haemoglobin distribution width (HDW) in female rats was statistically significantly higher than controls at 300 or 1000 mg/kg/day (p≤0.01).These changes were marginal, with most or all individual values within the historical control range, and as they had no effect on the primary red cell parameters, were considered not to be adverse. Mean reticulocyte corpuscular volume (MCVr) in male rats given 1000 mg/kg/day was statistically significantly lower than the corresponding control mean. However, this was due to three high individual control values (i.e. values above the upper limit of the historical control range) rather than an effect of the test material.
White blood cell count in males given 1000 mg/kg/day was statistically significantly higher than controls (p≤0.05), primarily due to slight increases in absolute lymphocyte and monocyte counts. However, all individual values were within the historical control range and since these changes were minor in nature, considered not to be adverse. Plasma cholesterol in both sexes was higher compared to controls at 300 (p≤0.05 top≤0.01) and 1000 mg/kg/day (p≤0.01). All individual values, with the exception of one female given 1000 mg/kg/day, and one male given 300 or 1000 mg/kg/day, were within the historical control background ranges. Triglyceride concentration was statistically significantly higher in males given 300 or 1000 mg/kg/day (p≤0.05 andp≤0.01, respectively) but most individual values for were within the historical control background ranges. Plasma calcium was statistically significantly higher than controls in males at 1000 mg/kg/day (p≤0.001). However, all individual values were within the historical control background range. Statistically significant (p≤0.05) increases in plasma sodium concentration at 300 and 1000 mg/kg/day, and lowering of plasma chloride concentrations (p≤0.01) at 1000 mg/kg/day were observed in male rats, however most or all individual values were within the historical control range. These changes in plasma cholesterol, triglyceride, calcium, sodium, and chloride levels were relatively minor and, in the absence of corroborative pathology changes, were considered not to be adverse.
In male rats given 1000 mg/kg/day, group mean TSH concentration was 2.6-fold higher than controls (p≤0.01), where 7 out 10 males were above the mean historical control range. In females at this dose level, there was a similar 2.5-fold increase in TSH concentration when compared with corresponding controls where 4 out of 10 females were above the mean historical control range although, this did not achieve statistical significance. In female rats, there was a marginal, but statistically significant (p≤0.05) increase in group mean T4 concentration at 1000 mg/kg/day where 9 out 10 females were above the mean historical control range. The increase in TSH concentration was considered to be associated with the rodent-specific adaptive epithelial hypertrophy in the thyroid gland and, in the absence of any marked changes in T3 or T4 concentrations, this finding was considered to be non-adverse.
Several instances of hyper- and hypoactivity in the arena were observed in all dose groups during the weekly functional observations throughout the study in both sexes. However, as the incidence was low and the pattern and frequency of these observations not dose-related, this observation was not considered to be treatment-related. At 100 mg/kg/day on Day 77, two males had a straub tail and one female excessively reared in the arena. On Day 91 of the study, at 300 mg/kg/day, one male displayed an excessive response to tail-pinching. These observations were considered not to be treatment-related due to their infrequent and transient nature. At 1000 mg/kg/day, in males and females, there were two and one instances of slight salivation on removal from the home cage, respectively, and one instance of salivation in the arena in males. Mean movement counts and distance travelled for all groups, including control rats, generally decreased with time in both sexes. In males, there was a statistically significant increase in movement count and distance travelled during Period 1 at 300 and 1000 mg/kg/day (p≤0.05), but these differences were not dose-related. In female rats given 1000 mg/kg/day, during Period 1, there was a statistically significant increase in distance travelled (p≤0.05), and a decrease in time at rest (p≤0.05). Thereafter, there were no statistically significant intergroup differences in movement counts or distance travelled at any dose level, in either sex. As these inter-group differences were observed in Period 1 only and not at any other time point, they were considered unlikely to be treatment-related. Fore and hindlimb grip strength was statistically significantly increased in females at 1000 mg/kg/day (p≤0.05) compared with controls. However, as this reduction was not consistent between sexes, it was considered likely to be due to chance rather than any effect of the test material.
Gross necropsy did not reveal any remarkable treatment-related findings.
Body weight-related liver weight in female rats given 300 or 1000 mg/kg/day and in male rats at all dose levels were statistically significantly higher than controls (p≤0.05 top≤0.001). Most individual body weight-related liver weights for male rats given 1000 mg/kg/day were above the upper limit of the historical background range, with group mean relative liver weight being 35% and 17% higher than corresponding controls, for males and females respectively, correlating to the adaptive centrilobular hypertrophy of the liver seen microscopically. In male rats, mean absolute and body weight-related thyroid weights were statistically significantly higher (p≤0.05 top≤0.01) than the control mean across all dose groups in a dose-related manner, by up to 2.3-fold, correlating with the adaptive follicular epithelial hypertrophy seen microscopically in the thyroid. Most individual values were, however, within the historical background range. Body weight-related kidney weights for males (p≤0.001) and females (p≤0.05) given 1000 mg/kg/day were statistically significantly higher than controls, by 12% and 5%, respectively. All individual values were within the historical background range, and there were no microscopic correlates. Therefore, this change was considered not to be of toxicological significance. In males, absolute and body weight-related spleen weight was higher than controls by up to 24% at 1000 mg/kg/day (p≤0.001). All individual body weight-related spleen weights were within the historical background range, and there were no microscopic correlates, therefore this change was considered not to be of toxicological significance. Absolute epididymis weight at 300 and 1000 mg/kg/day was statistically significantly lower than controls (p≤0.05). However, this was not strictly dose-related, and there were no microscopic correlates, therefore this intergroup difference was considered to be due to chance rather than any effect of the test material.
Histopathology revealed treatment-related effects in the liver (hypertrophy centrilobular), thyroid glands (hypertrophy of the follicular epithelium and increased basophilia of colloid), and urinary bladder (hyperplasia of the urothelium). These effects in the liver and thyroid were considered to be rodent specific adaptive responses. Hyperplasia of the urothelium of the urinary bladder was considered likely to be a local effect.
Based on the lack of adverse treatment-related effects observed through the study period, the No Observed Adverse Effect Level (NOAEL) for 1,2-Cyclohexanedicarboxylic Acid, 1-butyl 2-(phenylmethyl) ester was determined to be 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.